Global Endoscopic Retrograde Cholangiopancreatography Market Size study & Forecast, by Product Type (Endoscopes, Endotherapy Devices, Imaging Devices, Energy Devices, Others), by Application (Biliary Sphincterotomy, Biliary Dilatation, Biliary Stenting, P

Global Endoscopic Retrograde Cholangiopancreatography Market Size study & Forecast, by Product Type (Endoscopes, Endotherapy Devices, Imaging Devices, Energy Devices, Others), by Application (Biliary Sphincterotomy, Biliary Dilatation, Biliary Stenting, Pancreatic Sphincterotomy, Pancreatic Duct Dilatation, Pancreatic Duct Stenting), by End-User (Hospitals & Clinics, Ambulatory Surgery Centers, Others) and Regional Analysis, 2023-2030

Global Endoscopic Retrograde Cholangiopancreatography Market is valued at approximately USD XXX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2023-2030. Endoscopy is a medical procedure used to do certain minor surgery or to carefully examine tissues in the body or internal organs. Devices for endoscopic retrograde cholangiopancreatography (ERCP) are medical tools made for diseases relating to the pancreas and biliary system. Due to an increase in the prevalence of various bile duct, pancreatic, and liver disorders like Barrett's disease, biliary disease, Crohn's disease, colitis, gastroesophageal reflux disorder (GERD), pancreatitis, inflammatory bowel disease, liver disease, Crohn's disease, and peptic ulcer disease, these devices are becoming more and more important as well as used more frequently. The key factors such as rising incidence of cancer, rising investments, funds, and grants by governments and healthcare organizations to improve endoscopy research, and growing preference for minimally invasive surgeries are anticipated to create a lucrative demand for the market during forecast period.

Moreover, the rising prevalence of pancreatic cancer is one of the factors driving the growth of the Endoscopic Retrograde Cholangiopancreatography (ERCP) market. ERCP is a procedure used to diagnose and treat diseases of the bile and pancreatic ducts, including pancreatic cancer. According to the American Society of Clinical Oncology (ASCO), in Sept. 2021, pancreatic cancer was diagnosed in 31,950 men and 28,480 women in the United States. This disorder contributes to about 3% of all cancers. Pancreatic cancer is the tenth most common disease in males and the eighth most common cancer in women. About 1% more cases of pancreatic cancer are reported annually. As the incidence of pancreatic cancer increases, there is a growing need for diagnostic and therapeutic procedures such as ERCP. ERCP allows for the visualization and treatment of pancreatic and biliary diseases, such as pancreatic cancer, through a minimally invasive approach. Additionally, rising focus on investments by hospitals for advanced endoscopy instruments and rising adoption of single-use endoscopy instruments are anticipated to create a lucrative opportunity for the market during the forecast period. However, the high cost of Endoscopic Retrograde Cholangiopancreatography stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Endoscopic Retrograde Cholangiopancreatography Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players, rising prevalence of cancer, and product innovation and development in the region. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as increase in incidences of gastrointestinal and chronic biliary disorders, rising frequencies of benign tumors of the liver and pancreas, growing ageing population in the region.

Major market players included in this report are:
Olympus Corporation (Japan)
CONMED Corporation (US)
Fujifilm Holdings Corporation (Japan)
HOYA Corporation (Japan)
KARL STORZ SE & Co. KG (Germany)
Ambu A/S (Denmark)
Boston Scientific Corporation (US)
Johnson & Johnson (US)
Medtronic, PLC (Ireland)
Cook Medical (US)

Recent Developments in the Market:
In Jan. 2022, An endoscopic clipping tool named Instinct Plus was launched by Cook Medical (US). It is compatible with a duodenoscope and has uses in the GI tract for prophylactic clipping, anchoring treatments, and defect closure.

Global Endoscopic Retrograde Cholangiopancreatography Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product Type, Application, End-User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product Type:
Endoscopes
Endotherapy Devices
Imaging Devices
Energy Devices
Others

By Application:
Biliary Sphincterotomy
Biliary Dilatation
Biliary Stenting
Pancreatic Sphincterotomy
Pancreatic Duct Dilatation
Pancreatic Duct Stenting
By End-User:
Hospitals & Clinics
Ambulatory Surgery Centers
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Olympus Corporation (Japan)
CONMED Corporation (US)
Fujifilm Holdings Corporation (Japan)
HOYA Corporation (Japan)
KARL STORZ SE & Co. KG (Germany)
Ambu A/S (Denmark)
Boston Scientific Corporation (US)
Johnson & Johnson (US)
Medtronic, PLC (Ireland)
Cook Medical (US)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.